Department of Dermatology, Zurich University Hospital, Zurich, Switzerland.
Faculty of Medicine, University of Zurich, Zurich, Switzerland.
Exp Dermatol. 2018 Jun;27(6):694-696. doi: 10.1111/exd.13543.
Methadone (Met) mainly acts as a μ-opioid receptor agonist. Recent evidence pointing towards the role of Met in sensitization of certain cancer cell lines to chemotherapeutic agents has promoted the hypothesis that Met may be a useful adjuvant to cancer chemotherapy. We wanted to address whether Met has, alone or in combination with a chemotherapeutic agent, an effect on melanoma cell viability in vitro. Only a small fraction (4.3%) of our 102 melanoma biobank cell lines with RNA-sequencing data showed expression of the main receptor for Met (OPRM1). We assessed the viability of melanoma cell lines with high, medium or low/no OPRM1 expression (OPRM1 , OPRM1 , OPRM1 ) 72 hours after treatment with Met alone or combined with cisplatin (Cis). Our analyses show that Met alone did not affect cell viability. While Cis/Met treatment did not have an effect on viability of OPRM1 or OPRM1 cell lines, it resulted in a slightly decreased cell viability of OPRM1 cells. Clinically, concurrent temozolomide/Met treatment did not have an effect in our single-case report of a patient suffering from uveal melanoma. Taken together, our findings do not provide evidence for recommending Met as an adjuvant to chemotherapy in patients with melanoma.
美沙酮（Met）主要作为μ-阿片受体激动剂发挥作用。最近有证据表明，Met 可使某些癌细胞系对化疗药物产生致敏作用，这一发现促使人们提出假设，即 Met 可能是化疗的一种有用辅助药物。我们希望确定 Met 单独或与化疗药物联合使用时，对体外黑素瘤细胞活力是否有影响。在我们的 102 个具有 RNA 测序数据的黑素瘤生物库细胞系中，只有一小部分（4.3%）表达 Met 的主要受体（OPRM1）。我们评估了高、中或低/无 OPRM1 表达（OPRM1+、OPRM1++和 OPRM1-）的黑素瘤细胞系在单独使用 Met 或与顺铂（Cis）联合治疗 72 小时后的活力。我们的分析表明，Met 单独使用不会影响细胞活力。虽然 Cis/Met 治疗对 OPRM1+或 OPRM1++细胞系的活力没有影响，但它导致 OPRM1-细胞的活力略有下降。在临床上，我们对一名患有葡萄膜黑色素瘤的患者进行的单病例报告显示，同时使用替莫唑胺/Met 治疗没有效果。综上所述，我们的研究结果并未提供证据支持将 Met 推荐为黑素瘤患者化疗的辅助药物。
